Table 4.

Multivariate analysis (overall population; n = 128).

	Relapse/progression		NRM		PFS		OS		Acute GVHD II-IV		Chronic GVHD
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Female vs. male	1.72 (0.65–4.56)	0.278	3.94 (1.44–10.8)	0.0075	2.5 (1.26–4.96)	0.00876	2.61 (1.2–5.67)	0.0152	1.59 (0.69–3.69)	0.28	0.67 (0.3–1.5)	0.329
Adults vs. children	3.72 (1.38–10)	0.0092	1.09 (0.45–2.66)	0.852	2.07 (1.1–3.88)	0.0232	1.24 (0.6–2.56)	0.569	0.968 (0.4–2.32)	0.942	3.75 (1.67–8.39)	0.00133
Year of transplant	0.973 (0.86–1.1)	0.653	0.858 (0.78–0.948)	0.00248	0.908 (0.84–0.98)	0.013	0.885 (0.82–0.959)	0.00293	0.943 (0.85–1.04)	0.243	0.875 (0.79–0.97)	0.0087
Immune cytopenia vs. other	2.05 (0.75–5.63)	0.163	0.865 (0.35–2.16)	0.756	1.18 (0.61–2.28)	0.617	1.62 (0.78–3.35)	0.193	1.41 (0.62–3.24)	0.414	0.698 (0.29–1.69)	0.427
MRD vs. other donors	1.79 (0.66–4.86)	0.255	0.56 (0.22–1.46)	0.235	0.949 (0.48–1.86)	0.879	0.819 (0.39–1.74)	0.602	0.244 (0.08–0.746)	0.0133	0.603 (0.24–1.53)	0.286
RIC vs. MAC	1.69 (0.63–4.53)	0.294	0.306 (0.12–0.814)	0.0176	0.69 (0.36–1.31)	0.258	0.648 (0.31–1.34)	0.243	0.87 (0.38–2.01)	0.744	0.998 (0.46–2.19)	0.995
Centers	NA (0.65–4.56)	0.952	NA (1.44–10.8)	0.953	NA (1.26–4.96)	0.943	NA (1.2–5.67)	0.945	NA (0.69–3.69)	0.948	NA (0.3–1.5)	0.948

The table showed details of the multivariate analysis based on AD diagnosis (hematological vs. non-hematological diseases), sex, age at HSCT (cut-off for adults at 18 years), donor type (matched related donor vs. others), year of HSCT (before or after 2009), conditioning regimen (myeloablative vs. reduced-intensity conditioning) and centers. MAC, myeloablative conditioning regimen; RIC, reduced-intensity conditioning regimen; MRD, matched related donor. Bold values are intended as statistically significant.